Vioxx Re-Approval Standards Outlined In FDA Memo
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will need to address FDA's concerns that rofecoxib may be associated with a higher risk for cardiovascular events, the agency says in a memo outlining rationale on COX-2 inhibitors. Additional advisory committee review would be needed to consider Vioxx-specific regulatory options, FDA says.